Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of Daridorexant on Nighttime Respiratory Function and Sleep in Patients With Severe Obstructive Sleep Apnea

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of Daridorexant on Nighttime Respiratory Function and Sleep in Patients With Severe Obstructive Sleep Apnea

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Sponsors Idorsia Pharmaceuticals

    • Most Recent Events

    • 17 Sep 2024 According to an Idorsia Pharmaceuticals media release, data from this study will be presented at Sleep Europe 2024 - the 27th Congress of the European Sleep Research Society (ESRS), taking place in Seville, Spain, September 24-27, 2024.
    • 03 Apr 2023 Status changed from recruiting to completed.
    • 21 Sep 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top